Telix Pharmaceuticals (ASX:TLX) named New York Stock Exchange-listed healthcare company Cardinal Health as one of the commercial radiopharmaceutical distributors of its prostate cancer imaging agent, Gozellix, according to a Tuesday statement.

Gozellix is slated for commercial launch in the first half of this year. The agreement will enable Cardinal Health to supply finished unit doses of Gozellix using Telix's Aartms Quantm Irradiation System cyclotron technology, per the statement.

The imaging agent received the US Food and Drug Administration's approval in March.